The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression
Open accessAbstract
The tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not normal cells; its role in normal nontransformed tissues is unknown. We report here that chronic blockade of TRAIL in mice exacerbated autoimmune arthritis, and that intraarticular TRAIL gene transfer ameliorated the disease. In vivo, TRAIL blockade led to profound hyperproliferation of synovial cells and arthritogenic lymphocytes and heightened the production of cytokines and autoantibodies. In vitro, TRAIL inhibited DNA synthesis and prevented cell cycle progression of lymphocytes. Interestingly, TRAIL had no effect on apoptosis of inflammatory cells either in vivo or in vitro. Thus, unlike other members of the tumor necrosis factor superfamily, TRAIL is a prototype inhibitor protein that inhibits autoimmune inflammation by blocking cell cycle progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 2×
“In vivo administration of recombinant TRAIL selectively kills tumor cells but not normal cells, leaving the host organ systems unharmed (13, 14).”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
Ju, S.-T., Panka, D. J., Cui, H., Ettinger, R., EI-Khatib, M., Sherr, D. H., Stanger, B. Z., & Marshak-Rothstein, A. (1995) · Nature · doi:10.1038/373444a0 · Cited by 1,499
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Current protocols in immunology
Nezlin, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,408
Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., et al. (1995) · Nature · doi:10.1038/373441a0 · Cited by 1,314
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Fas and Fas ligand: lpr and gld mutations
Nagata, S., & Suda, T. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80069-7 · Cited by 892
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB
Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., & Tschopp, J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80401-x · Cited by 696
Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection
Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997) · Science · doi:10.1126/science.276.5314.960 · Cited by 622
Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis
Giordano, C., Stassi, G., De Maria, R., Todaro, M., Richiusa, P., Papoff, G., Ruberti, G., Bagnasco, M., Testi, R., & Galluzzo, A. (1997) · Science · doi:10.1126/science.275.5302.960 · Cited by 582
(2008) · Arthritis & Rheumatism · doi:10.1002/art.23363 · Cited by 505
The Role of Fas in Autoimmune Diabetes
Chervonsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A., & Matis, L. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80178-6 · Cited by 496
Current protocols in protein science
Howland, J. L. (1996) · Biochemical Education · doi:10.1016/s0307-4412(96)80025-2 · Cited by 462
Kang, S.-M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., & Baekkeskov, S. (1997) · Nature Medicine · doi:10.1038/nm0797-738 · Cited by 450
Sheikh, M. S., Burns, T. F., Huang, Y., Wu, G. S., Amundson, S. A., Brooks, K., Fornace, A. J., & El‐Deiry, W. S. (1998) · PubMed · Cited by 428
Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Sneller, M. C., Wang, J., Dale, J. K., Strober, W., Middelton, L. A., Choi, Y., Fleisher, T. A., Lim, M. S., Jaffe, E. S., Puck, J. M., et al. (1997) · Blood · doi:10.1182/blood.v89.4.1341 · Cited by 371
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
Pan, G., Ni, J., Yu, G.-L., Wei, Y.-F., & Dixit, V. M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00135-5 · Cited by 317
Characterization of two receptors for TRAIL1
Schneider, P., Bodmer, J.-L., Thome, M., Hofmann, K., Holler, N., & Tschopp, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01231-3 · Cited by 290
TRAIL/Apo-2-ligand-induced apoptosis in human T cells
Jeremias, I., Herr, I., Boehler, T., & Debatin, K.-M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<143::aid-immu143>3.0.co;2-3 · Cited by 267
Wu, G. S., Burns, T. F., Zhan, Y.-A., Alnemri, E. S., & El‐Deiry, W. S. (1999) · PubMed · Cited by 238
Requirement of Fas for the Development of Autoimmune Diabetes in Nonobese Diabetic Mice
Itoh, N., Imagawa, A., Hanafusa, T., Waguri, M., Yamamoto, K., Iwahashi, H., Moriwaki, M., Nakajima, H., Miyagawa, J., Namba, M., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.4.613 · Cited by 236
Chen, Y., Inobe, J., & Weiner, H. L. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.2.910 · Cited by 216
Self-citationFas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
Waldner, H., Sobel, R. A., Howard, E., & Kuchroo, V. K. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3100 · Cited by 199
Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
Zhang, H., Yang, Y., Horton, J. L., Samoilova, E. B., Judge, T. A., Turka, L. A., Wilson, J. M., & Chen, Y. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119726 · Cited by 199
Self-citationThe lpr and gld genes in systemic autoimmunity: life and death in the Fas lane
Cohen, P. L., & Eisenberg, R. A. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90066-g · Cited by 197
Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
Mariani, S. M., & Krammer, P. H. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199805)28:05<1492::aid-immu1492>3.0.co;2-x · Cited by 192
Bettinardi, A., Brugnoni, D., Quiròs-Roldan, E., Malagoli, A., La Grutta, S., Correra, A., & Notarangelo, L. D. (1997) · Blood · doi:10.1182/blood.v89.3.902 · Cited by 190
Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease
MAINI, R. N., ELLIOTT, M. J., BRENNAN, E. M., WILLIAMS, R. O., CHU, C. Q., PALEOLOG, E., CHARLES, P. J., TAYLOR, P. C., & FELDMANN, M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00070.x · Cited by 181
Sabelko, K. A., Kelly, K. A., Nahm, M. H., Cross, A. H., & Russell, J. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3096 · Cited by 150
Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice.
Fujisawa, K., Asahara, H., Okamoto, K., Aono, H., Hasunuma, T., Kobata, T., Iwakura, Y., Yonehara, S., Sumida, T., & Nishioka, K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118789 · Cited by 119
Essential role of T cell NF-kappa B activation in collagen-induced arthritis.
Seetharaman, R., Mora, A. L., Nabozny, G. H., Boothby, M. R., & Chen, J. (1999) · PubMed · Cited by 88
Essential Role of T Cell NF-κB Activation in Collagen-Induced Arthritis
Seetharaman, R., Mora, A. L., Nabozny, G. H., Boothby, M. R., & Chen, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1577 · Cited by 76
Muruve, D. A., Nicolson, A. G., Manfro, R. C., Strom, T. B., Sukhatme, V. P., & Libermann, T. A. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.8-955 · Cited by 73
Eliaz, R. E., Wallach, D., & Kost, J. (1996) · Cytokine · doi:10.1006/cyto.1996.0065 · Cited by 25
Cited by
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
Overview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Luo, J.-L., Maeda, S., Hsu, L.-C., Yagita, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 603
Metadata
- Authors
- Song, K., Chen, Y., Göke, R., Wilmen, A., Seidel, C., Göke, A., Hilliard, B., & Chen, Y.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2000-03-27
- Volume
- 191
- Issue
- 7
- Pages
- 1095-1104
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2142790993
- Cited by
- 359
- References
- 46
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.